Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
AB Sciex
RANDOX LABORATORIES

IVD Market Expected to Grow Substantially in 2012-2014

By Labmedica International staff writers
Posted on 13 Dec 2011
The global in vitro diagnostics (IVD) market is expected to grow in 2012-2014 following a surge in Mergers and Acquisitions (M&A) deal values, an acceleration of companion diagnostics partnerships, and the emergence of new prospects for early detection testing, according to Diagnostics 2011, PwC's (New York, NY, USA) biennial review of the IVD sector.

Financial investors, life sciences research groups, clinical laboratories, and medical technology players are all entering the IVD market. Multibillion dollar IVD deals in first seven months of 2011 more than triple total M&A deal value from 2010 to more than US $15 billion.

Several companies are driving the development of a wave of new tests for early detection of major cancers. If the market adopts the concept of using noninvasive in vitro diagnostics for early detection, a major diagnostics or pharmaceutical company could move to acquire one or several of the promising new ventures in this field.

"The IVD sector has attracted exceptional levels of interest, especially reflected in the acceleration of companion diagnostics partnerships with pharmaceutical companies. This momentum will continue as long as innovation and growth prospects in key market segments, such as molecular and tissue diagnostics, remain strong, and rapid action is taken by stakeholders to create a favorable environment for sustaining such innovation, including pricing, regulatory pathways, clinical trial design, reimbursement, and drug-diagnostic value-sharing," said Loic Kubitza, director, pharmaceutical & life sciences advisory services, PwC Luxembourg, and author of the Diagnostics 2011 report.

PwC's Pharmaceutical, Medical Device and Life Sciences industry group is dedicated to delivering effective solutions to the strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical device companies.

Related Links:

PwC





ADVANCED INSTRUMENTS
DiagCor Bioscience
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.